Looking ahead, a thorough evaluation of patients’ aPL profile, in combination with transcriptomic and epigenomic data analysis, may contribute to explaining the clinical heterogeneity of APS and lead to the development of more accurate prognostic and therapeutic protocols. This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.